You can buy or sell Dynavax and other stocks, options, ETFs, and crypto commission-free!
Dynavax Technologies Corporation Common Stock, also called Dynavax, is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. Read More It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
52 Week High
52 Week Low
Simply Wall StMar 21
Should You Worry About Dynavax Technologies Corporation’s (NASDAQ:DVAX) CEO Pay?
Eddie Gray has been the CEO of Dynavax Technologies Corporation (NASDAQ:DVAX) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization.
Seeking AlphaMar 13
Dynavax Technologies (DVAX) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow
The following slide deck was published by Dynavax Technologies Corporation in conjunction with this event. 1 20 Click to enlarge Notes:...
The Motley FoolMar 7
Why Dynavax Technologies Cratered in February
What happened Shares of Dynavax Technologies (NASDAQ:DVAX), a vaccine and immuno-oncology specialist, dropped by 15.9% last month, according to data from S&P Global Market Intelligence. What sparked this sell-off? Dynavax's stock tanked after the company reported its fourth-quarter and full-year results toward the end of February. While the biotech actually beat Wall Street's consensus estimate on revenue for the fourth quarter, investors were apparently hoping the company would announce a partnering deal...
Expected May 7, After Hours